DDX19B

Across TCGA pan-cancer cohorts, DDX19B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of DDX19B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DDX19B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DDX19B is over-expressed in tumor, although a few such as HNSC and PDAC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where DDX19B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DDX19B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.328	<.001	12	view →
HNSC	All	III,IV	−0.280	<.001	11	view →
PDAC	Female	II,III,IV	−0.428	<.001	8	view →
LSCC	Male	All	−0.315	<.001	7	view →
COAD	All	All	−0.074	.031	2	view →
LUAD	Male	All	−0.090	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

DDX19B–CCRCC

Open the CCRCC breakdown →